Titan Pharmaceuticals, Inc.(TTNP)Earnings, Financials & Key Ratios
TTNP•NASDAQ
$3.08
$4M mkt cap·Price updated May 1, 2026
AboutTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.Show more
- Revenue$0-100.0%
- EBITDA-$5M+36.5%
- Net Income-$5M+15.5%
- EPS (Diluted)-5.23+29.4%
- ROE-103.63%+25.5%
- ROIC-12206.25%
TTNP Key Insights
Titan Pharmaceuticals, Inc. (TTNP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Shares diluted 19.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TTNP Price & Volume
Titan Pharmaceuticals, Inc. (TTNP) stock price & volume — 10-year historical chart
Loading chart...
TTNP Growth Metrics
Titan Pharmaceuticals, Inc. (TTNP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-88.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.15%
Return on Capital
10 Years-143.02%
5 Years-187.53%
3 Years-194.61%
Last Year-100.35%
TTNP Peer Comparison
Titan Pharmaceuticals, Inc. (TTNP) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 MTLS | 321.33M | 5.44 | 35.61 | -3.63% | 2.66% | 2.95% | 0.26 | |
 ORMP | 159.7M | 3.91 | -8.32 | -100% | -12.08% | -15.73% | 0.00 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 COLL | 1.27B | 39.32 | 22.73 | 23.62% | 9.41% | 26.74% | 3.12 | |
 MNKD | 1.1B | 3.55 | 177.50 | 22.23% | -6.63% | |||
 ABBV | 358.42B | 202.64 | 85.50 | 8.57% | 6.91% | 62.15% | ||
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 |
Compare TTNP vs Peers
Titan Pharmaceuticals, Inc. (TTNP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TTNP Income Statement
Titan Pharmaceuticals, Inc. (TTNP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 15.06M | 215K | 5.91M | 3.61M | 4.84M | 1.53M | 60K | 1K | 0 | 10K |
| Revenue Growth % | 801.56% | -98.57% | 2649.3% | -38.91% | 33.98% | -68.46% | -96.07% | -98.33% | -100% | -88.24% |
| Cost of Goods Sold | 6.13M | 9.65M | 538K | 1.29M | 472K | 199K | 196K | 0 | 5K | 0 |
| COGS % of Revenue | 40.66% | 4487.44% | 9.1% | 35.67% | 9.76% | 13.04% | 326.67% | - | - | - |
| Gross Profit | 8.94M▲ 0% | -9.43M▼ 205.5% | 5.37M▲ 157.0% | 2.32M▼ 56.8% | 4.37M▲ 87.9% | 1.33M▼ 69.6% | -136K▼ 110.2% | 1K▲ 100.7% | -5K▼ 600.0% | 5K▲ 0% |
| Gross Margin % | 59.34% | -4387.44% | 90.9% | 64.33% | 90.24% | 86.96% | -226.67% | 100% | - | 50% |
| Gross Profit Growth % | 397.57% | -205.53% | 156.96% | -56.77% | 87.95% | -69.61% | -110.25% | 100.74% | -600% | - |
| Operating Expenses | 10.72M | 14.72M | 13.64M | 19.17M | 11.72M | 10.68M | 10.29M | 7.28M | 4.56M | 2.61M |
| OpEx % of Revenue | 71.17% | 6845.12% | 230.71% | 530.79% | 242.19% | 699.93% | 17158.33% | 727800% | - | - |
| Selling, General & Admin | 4.6M | 5.07M | 6.87M | 11.93M | 5.8M | 4.99M | 6.03M | 5.55M | 4.56M | 2.61M |
| SG&A % of Revenue | 30.51% | 2357.67% | 116.16% | 330.24% | 119.9% | 326.93% | 10056.67% | 554800% | - | - |
| Research & Development | 6.13M | 9.65M | 7.48M | 7.24M | 5.92M | 5.69M | 4.76M | 1.91M | 0 | 0 |
| R&D % of Revenue | 40.66% | 4487.44% | 126.51% | 200.55% | 122.28% | 373% | 7930% | 191300% | - | - |
| Other Operating Expenses | 0 | -55K | -6K | 17K | 0 | -84K | -497K | -183K | 0 | 0 |
| Operating Income | 4.34M▲ 0% | -14.5M▼ 433.9% | -8.26M▲ 43.0% | -16.84M▼ 103.8% | -7.35M▲ 56.4% | -9.35M▼ 27.2% | -10.23M▼ 9.4% | -7.28M▲ 28.9% | -4.56M▲ 37.4% | -2.61M▲ 0% |
| Operating Margin % | 28.83% | -6745.12% | -139.81% | -466.46% | -151.94% | -612.98% | -17058.33% | -727700% | - | -26110% |
| Operating Income Growth % | 164.26% | -433.92% | 43.01% | -103.82% | 56.36% | -27.25% | -9.42% | 28.9% | 37.38% | - |
| EBITDA | 4.72M | -14.09M | -7.88M | -16.6M | -7.06M | -9.13M | -10.04M | -7.17M | -4.55M | -2.61M |
| EBITDA Margin % | 31.33% | -6551.16% | -133.38% | -459.71% | -145.91% | -598.49% | -16731.67% | -716500% | - | -26110% |
| EBITDA Growth % | 173.74% | -398.41% | 44.03% | -110.55% | 57.48% | -29.38% | -9.92% | 28.63% | 36.47% | 63.19% |
| D&A (Non-Cash Add-back) | 377K | 417K | 380K | 244K | 292K | 221K | 196K | 112K | 5K | 0 |
| EBIT | 4.34M | -14.5M | -8.26M | -6.52M | -7.35M | -9.35M | -10.23M | -7.28M | -4.71M | -2.61M |
| Net Interest Income | 37K | -369K | -887K | -967K | -769K | 1K | 53K | 5K | 1K | -1K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 1K | 53K | 5K | 1K | -1K |
| Interest Expense | 37K | 369K | 887K | 967K | 769K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 792K | 195K | -759K | 386K | -56K | 578K | 29K | 1.71M | -149K | -194K |
| Pretax Income | 5.13M▲ 0% | -14.31M▼ 378.6% | -9.02M▲ 36.9% | -16.46M▼ 82.4% | -7.41M▲ 55.0% | -8.78M▼ 18.5% | -10.21M▼ 16.3% | -5.57M▲ 45.4% | -4.71M▲ 15.5% | -2.81M▲ 0% |
| Pretax Margin % | 34.09% | -6654.42% | -152.65% | -455.77% | -153.1% | -575.1% | -17010% | -556900% | - | -28050% |
| Income Tax | 0 | 0 | 0 | -369K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 2.24% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 5.13M▲ 0% | -14.31M▼ 378.6% | -9.02M▲ 36.9% | -16.09M▼ 78.3% | -20.73M▼ 28.8% | -8.11M▲ 60.9% | -10.18M▼ 25.4% | -5.57M▲ 45.3% | -4.71M▲ 15.5% | -2.81M▲ 0% |
| Net Margin % | 34.09% | -6654.42% | -152.65% | -445.56% | -428.44% | -531.72% | -16961.67% | -556900% | - | -28050% |
| Net Income Growth % | 145.53% | -378.62% | 36.93% | -78.31% | -28.83% | 60.85% | -25.43% | 45.28% | 15.5% | 48.64% |
| Net Income (Continuing) | 5.13M | -14.31M | -9.02M | -7.49M | -7.41M | -8.78M | -10.21M | -5.57M | -4.71M | -2.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -10.84M | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 36.01▲ 0% | -121.34▼ 437.0% | -47.59▲ 60.8% | -9.83▲ 79.3% | -10.38▼ 5.6% | -4.06▲ 60.9% | -15.15▼ 273.2% | -7.41▲ 51.1% | -5.23▲ 29.4% | -2.63▲ 0% |
| EPS Growth % | 135.57% | -436.96% | 60.78% | 79.34% | -5.6% | 60.89% | -273.15% | 51.09% | 29.42% | 54.15% |
| EPS (Basic) | 44.71 | -121.48 | -47.59 | -12602.35 | -10.38 | -4.06 | -15.15 | -7.41 | -5.23 | - |
| Diluted Shares Outstanding | 119.21K | 117.91K | 189.6K | 1.64M | 2M | 2M | 671.7K | 752K | 899K | 1.06M |
| Basic Shares Outstanding | 115.21K | 117.78K | 189.6K | 1.28K | 2M | 2M | 671.7K | 752K | 899K | 1.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TTNP Balance Sheet
Titan Pharmaceuticals, Inc. (TTNP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.83M | 8.31M | 13.3M | 8.31M | 7.33M | 7.23M | 3.6M | 8.02M | 2.92M | 3.05M |
| Cash & Short-Term Investments | 14.01M | 7.52M | 9.29M | 5.22M | 5.41M | 6.04M | 2.94M | 6.76M | 2.83M | 2.8M |
| Cash Only | 14.01M | 7.52M | 9.29M | 5.22M | 5.41M | 6.04M | 2.94M | 6.76M | 2.83M | 2.8M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.59M | 65K | 1.84M | 438K | 884K | 112K | 36K | 1.05M | 62K | 143K |
| Days Sales Outstanding | 86.91 | 110.35 | 113.37 | 44.27 | 66.69 | 26.79 | 219 | 381.79K | - | 3.08K |
| Inventory | 0 | 0 | 1.26M | 998K | 328K | 293K | 106K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 856.19 | 282.82 | 253.64 | 537.41 | 197.4 | - | - | - |
| Other Current Assets | 237K | 361K | 361K | 1.55M | 181K | 307K | 524K | 212K | 30K | 105K |
| Total Non-Current Assets | 837K | 595K | 794K | 1.21M | 759K | 765K | 455K | 68K | 0 | 0 |
| Property, Plant & Equipment | 837K | 595K | 794K | 1.21M | 759K | 717K | 407K | 68K | 0 | 0 |
| Fixed Asset Turnover | 18.00x | 0.36x | 7.44x | 2.97x | 6.37x | 2.13x | 0.15x | 0.01x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | -1.21M | -759K | 48K | 48K | 0 | 0 | 0 |
| Total Assets | 18.67M▲ 0% | 8.9M▼ 52.3% | 14.1M▲ 58.3% | 9.52M▼ 32.4% | 8.09M▼ 15.1% | 7.99M▼ 1.1% | 4.06M▼ 49.2% | 8.09M▲ 99.3% | 2.92M▼ 63.9% | 3.05M▲ 0% |
| Asset Turnover | 0.81x | 0.02x | 0.42x | 0.38x | 0.60x | 0.19x | 0.01x | 0.00x | - | 0.00x |
| Asset Growth % | 40.49% | -52.3% | 58.28% | -32.44% | -15.07% | -1.15% | -49.24% | 99.26% | -63.85% | -225.25% |
| Total Current Liabilities | 4.86M | 4.46M | 3.45M | 3.6M | 4.22M | 2.67M | 2.63M | 1.44M | 483K | 263K |
| Accounts Payable | 3.02M | 821K | 1.53M | 815K | 1.25M | 795K | 695K | 348K | 202K | 219K |
| Days Payables Outstanding | 179.64 | 31.06 | 1.04K | 230.96 | 968.95 | 1.46K | 1.29K | - | 14.75K | - |
| Short-Term Debt | 0 | 3M | 527K | 272K | 477K | 112K | 0 | 500K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 313K | 0 | 533K | 295K | 196K | 12K | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 1.81M | 1.81M | 1.03M | 129K | 0 | 0 | 0 |
| Current Ratio | 3.67x | 1.86x | 3.85x | 2.31x | 1.74x | 2.71x | 1.37x | 5.55x | 6.05x | 6.05x |
| Quick Ratio | 3.67x | 1.86x | 3.49x | 2.03x | 1.66x | 2.60x | 1.33x | 5.55x | 6.05x | 6.05x |
| Cash Conversion Cycle | - | - | -65.74 | 96.13 | -648.61 | -893.96 | -877.86 | - | - | 3.08K |
| Total Non-Current Liabilities | 619K | 3.58M | 3.81M | 4.49M | 332K | 187K | 65K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 3.58M | 3.79M | 4.02M | 332K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 150K | 0 | 187K | 65K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 619K | 0 | 25K | 320K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.48M | 8.05M | 7.26M | 8.09M | 4.55M | 2.86M | 2.69M | 1.44M | 483K | 263K |
| Total Debt | 0 | 6.58M | 4.31M | 4.44M | 809K | 299K | 187K | 565K | 0 | 0 |
| Net Debt | -14.01M | -938K | -4.98M | -782K | -4.6M | -5.74M | -2.75M | -6.2M | -2.83M | -2.8M |
| Debt / Equity | - | 7.68x | 0.63x | 3.10x | 0.23x | 0.06x | 0.14x | 0.09x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | -2.97x | - | - | - | - | - | - | - | - | 1.07x |
| Interest Coverage | 117.38x | -39.30x | -9.32x | -17.42x | -9.56x | - | - | - | - | - |
| Total Equity | 13.19M▲ 0% | 857K▼ 93.5% | 6.83M▲ 697.1% | 1.43M▼ 79.0% | 3.53M▲ 146.5% | 5.14M▲ 45.5% | 1.36M▼ 73.5% | 6.64M▲ 387.3% | 2.44M▼ 63.3% | 2.79M▲ 0% |
| Equity Growth % | 88.71% | -93.5% | 697.08% | -79.02% | 146.48% | 45.47% | -73.47% | 387.31% | -63.26% | -222.9% |
| Book Value per Share | 110.66 | 7.27 | 36.03 | 0.88 | 1.77 | 2.57 | 2.03 | 8.83 | 2.71 | 2.62 |
| Total Shareholders' Equity | 13.19M | 857K | 6.83M | 1.43M | 3.53M | 5.14M | 1.36M | 6.64M | 2.44M | 2.79M |
| Common Stock | 297.86M | 297.86M | 13K | 57K | 7K | 10K | 1K | 1K | 1K | 1K |
| Retained Earnings | -308.96M | -323.27M | -332.58M | -349.04M | -367.28M | -376.06M | -386.26M | -391.83M | -396.54M | -397.79M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3.64M | -4.06M | -4.44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TTNP Cash Flow Statement
Titan Pharmaceuticals, Inc. (TTNP) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 6.29M | -13.04M | -8.43M | -15.45M | -17.2M | -7.9M | -8.18M | -7.09M | -3.88M | -3.88M |
| Operating CF Margin % | 41.77% | -6064.19% | -142.63% | -427.72% | -355.58% | -517.63% | -13638.33% | -709200% | - | - |
| Operating CF Growth % | 184.29% | -307.18% | 35.34% | -83.19% | -11.38% | 54.08% | -3.6% | 13.33% | 45.29% | 165.39% |
| Net Income | 5.13M | -14.31M | -9.02M | -16.46M | -18.24M | -8.78M | -10.21M | -5.57M | -4.71M | -2.81M |
| Depreciation & Amortization | 377K | 417K | 380K | 244K | 292K | 221K | 196K | 112K | 5K | 0 |
| Stock-Based Compensation | 1.04M | 1.69M | 1.56M | 572K | 7K | 1.5M | 997K | 1.01M | 0 | 0 |
| Deferred Taxes | -1.04M | -619K | -134K | -1.34M | -760K | -661K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 214K | 141K | -803K | 572K | 482K | -5K | 452K | -1.73M | -2K | 0 |
| Working Capital Changes | 567K | -357K | -408K | 961K | 1.02M | -219K | 378K | -916K | 823K | 59K |
| Change in Receivables | -245K | 3.52M | -1.67M | 744K | 186K | 642K | 76K | -10K | 1.05M | 38K |
| Change in Inventory | 0 | 0 | 31K | 264K | 287K | 35K | 187K | 0 | 0 | 0 |
| Change in Payables | -1.14M | -2.19M | 542K | -125K | 1.1M | -1.19M | -751K | -476K | -145K | -137K |
| Cash from Investing | -171K | -175K | -416K | -256K | -540K | -23K | 0 | 732K | 0 | 0 |
| Capital Expenditures | -171K | -175K | -416K | -256K | -540K | -23K | 0 | -2K | 0 | 0 |
| CapEx % of Revenue | 1.14% | 81.4% | 7.04% | 7.09% | 11.16% | 1.51% | - | 200% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -133K | -175K | -579K | -267K | -540K | -23K | 0 | 734K | 0 | 0 |
| Cash from Financing | 27K | 6.73M | 10.62M | 11.27M | 17.93M | 8.84M | 4.98M | 10M | -62K | 1.46M |
| Debt Issued (Net) | 0 | 6.73M | -2.35M | 0 | -946K | 0 | 0 | 500K | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | -285K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 27K | 0 | 3.6M | 1.6M | 7.24M | 0 | 4K | 0 | -62K | -143K |
| Net Change in Cash | 6.15M▲ 0% | -6.48M▼ 205.4% | 1.77M▲ 127.3% | -4.43M▼ 350.0% | 190K▲ 104.3% | 919K▲ 383.7% | -3.2M▼ 448.1% | 3.64M▲ 213.8% | -3.94M▼ 208.3% | -1.29M▲ 0% |
| Free Cash Flow | 6.12M▲ 0% | -13.21M▼ 315.8% | -8.85M▲ 33.0% | -15.7M▼ 77.5% | -17.74M▼ 13.0% | -7.92M▲ 55.4% | -8.18M▼ 3.3% | -7.09M▲ 13.3% | -3.88M▲ 45.3% | -2.75M▲ 0% |
| FCF Margin % | 40.64% | -6145.58% | -149.67% | -434.81% | -366.74% | -519.13% | -13638.33% | -709400% | - | -27460% |
| FCF Growth % | 180.56% | -315.83% | 33.04% | -77.47% | -13.01% | 55.35% | -3.29% | 13.31% | 45.31% | 59.4% |
| FCF per Share | 51.36 | -112.06 | -46.66 | -9.60 | -8.88 | -3.97 | -12.18 | -9.43 | -4.32 | -4.32 |
| FCF Conversion (FCF/Net Income) | 1.23x | 0.91x | 0.93x | 0.96x | 0.83x | 0.97x | 0.80x | 1.27x | 0.82x | 0.98x |
| Interest Paid | 0 | 298K | 471K | 432K | 295K | 0 | 0 | 21K | 13K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TTNP Key Ratios
Titan Pharmaceuticals, Inc. (TTNP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 50.89% | -203.69% | -234.73% | -389.38% | -834.96% | -187.17% | -313.09% | -139.14% | -103.63% | -100.61% |
| Return on Invested Capital (ROIC) | - | - | -700.73% | -1010.24% | - | - | - | - | -12206.25% | -12206.25% |
| Gross Margin | 59.34% | -4387.44% | 90.9% | 64.33% | 90.24% | 86.96% | -226.67% | 100% | - | 50% |
| Net Margin | 34.09% | -6654.42% | -152.65% | -445.56% | -428.44% | -531.72% | -16961.67% | -556900% | - | -28050% |
| Debt / Equity | - | 7.68x | 0.63x | 3.10x | 0.23x | 0.06x | 0.14x | 0.09x | - | 0.00x |
| Interest Coverage | 117.38x | -39.30x | -9.32x | -17.42x | -9.56x | - | - | - | - | - |
| FCF Conversion | 1.23x | 0.91x | 0.93x | 0.96x | 0.83x | 0.97x | 0.80x | 1.27x | 0.82x | 0.98x |
| Revenue Growth | 801.56% | -98.57% | 2649.3% | -38.91% | 33.98% | -68.46% | -96.07% | -98.33% | -100% | -88.24% |
TTNP Frequently Asked Questions
Titan Pharmaceuticals, Inc. (TTNP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Titan Pharmaceuticals, Inc. (TTNP) reported $0.0M in revenue for fiscal year 2024. This represents a 90% decrease from $0.1M in 1995.
Titan Pharmaceuticals, Inc. (TTNP) saw revenue decline by 100.0% over the past year.
Titan Pharmaceuticals, Inc. (TTNP) reported a net loss of $2.8M for fiscal year 2024.
Dividend & Returns
Titan Pharmaceuticals, Inc. (TTNP) has a return on equity (ROE) of -103.6%. Negative ROE indicates the company is unprofitable.
Titan Pharmaceuticals, Inc. (TTNP) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More TTNP
Titan Pharmaceuticals, Inc. (TTNP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates